- Home
- PYN vs ANTX Comparison
PYN vs ANTX Comparison
Compare PYN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- ANTX
- Stock Information
- Founded
- PYN 2002
- ANTX 2017
- Country
- PYN United States
- ANTX United States
- Employees
- PYN N/A
- ANTX N/A
- Industry
- PYN Investment Managers
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- ANTX Health Care
- Exchange
- PYN Nasdaq
- ANTX Nasdaq
- Market Cap
- PYN 30.1M
- ANTX 33.2M
- IPO Year
- PYN N/A
- ANTX 2022
- Fundamental
- Price
- PYN $5.24
- ANTX $1.05
- Analyst Decision
- PYN
- ANTX Buy
- Analyst Count
- PYN 0
- ANTX 2
- Target Price
- PYN N/A
- ANTX $2.00
- AVG Volume (30 Days)
- PYN 19.9K
- ANTX 257.5K
- Earning Date
- PYN 01-01-0001
- ANTX 08-12-2025
- Dividend Yield
- PYN 5.07%
- ANTX N/A
- EPS Growth
- PYN N/A
- ANTX N/A
- EPS
- PYN N/A
- ANTX N/A
- Revenue
- PYN N/A
- ANTX N/A
- Revenue This Year
- PYN N/A
- ANTX N/A
- Revenue Next Year
- PYN N/A
- ANTX N/A
- P/E Ratio
- PYN N/A
- ANTX N/A
- Revenue Growth
- PYN N/A
- ANTX N/A
- 52 Week Low
- PYN $4.84
- ANTX $0.87
- 52 Week High
- PYN $6.60
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- PYN 43.64
- ANTX 42.32
- Support Level
- PYN $5.25
- ANTX $1.05
- Resistance Level
- PYN $5.37
- ANTX $1.11
- Average True Range (ATR)
- PYN 0.11
- ANTX 0.04
- MACD
- PYN 0.00
- ANTX 0.00
- Stochastic Oscillator
- PYN 4.30
- ANTX 0.00
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.